News | May 13, 2023
Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
Tatva Chintan Pharma Chem has reported total income of Rs. 125.35 crores during the period ended March 31, 2023
The collaboration between CORONA and Ferring will cater to patients across India
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated
